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In the present studywe investigatedwhether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathogen-
esis of Parkinson’s disease, also affects L-DOPA-induced dyskinesia. In striatal slices of naive rodents, N/OFQ (0.1–1M) prevented the
increase of ERK phosphorylation and the loss of depotentiation of synaptic plasticity induced by the D1 receptor agonist SKF38393 in
spiny neurons. In vivo, exogenous N/OFQ (0.03–1 nmol, i.c.v.) or a synthetic N/OFQ receptor agonist given systemically (0.01–1 mg/Kg)
attenuated dyskinesias expression in 6-hydroxydopamine hemilesioned rats primed with L-DOPA, without causing primary hypoloco-
motive effects. Conversely, N/OFQ receptor antagonists worsened dyskinesia expression. In vivo microdialysis revealed that N/OFQ
prevented dyskinesias simultaneously with its neurochemical correlates such as the surge of nigral GABA and glutamate, and the
reduction of thalamic GABA. Regional microinjections revealed that N/OFQ attenuated dyskinesias more potently and effectively when
microinjected in striatum than substantia nigra (SN) reticulata, whereas N/OFQ receptor antagonists were ineffective in striatum but
worsened dyskinesias when given in SN. Quantitative autoradiography showed an increase in N/OFQ receptor binding in striatum and a
reduction in SN of both unprimed and dyskinetic 6-hydroxydopamine rats, consistent with opposite adaptive changes of N/OFQ trans-
mission. Finally, the N/OFQ receptor synthetic agonist also reduced dyskinesia expression in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated dyskinetic macaques without affecting the global parkinsonian score. We conclude that N/OFQ receptor
agonists may represent a novel strategy to counteract L-DOPA-induced dyskinesias. Their action is possibly mediated by upregulated
striatal N/OFQ receptors opposing the D1 receptor-mediated overactivation of the striatonigral direct pathway.
Introduction
Nociceptin/orphanin FQ (N/OFQ) (Meunier et al., 1995; Reins-
cheid et al., 1995) and its receptor (NOP) represent a neuropep-
tide system bearing structural and functional analogies with
classical opioid systems but unique pharmacological profile
(Calo` et al., 2000). NOP receptor expression and binding are
widespread throughout the rodent and primate brain, support-
ing the role of the N/OFQ-NOP receptor system in the modula-
tion of central functions such as sensory nociceptive processing,
learning and memory, reward, mood, feeding, stress, and move-
ment (Mogil and Pasternak, 2001; Lambert, 2008).
Preclinical and clinical studies revealed a link betweenN/OFQ
and Parkinson’s disease (PD) (Marti et al., 2005, 2010). Indeed,
an increase of N/OFQ expression (Marti et al., 2005, 2010; Gouty
et al., 2010) and release (Marti et al., 2005) in the substantia nigra
(SN) of parkinsonian animals was found, together with an eleva-
tion of N/OFQ levels in the CSF of parkinsonian patients (Marti
et al., 2010). Consistent with a pathogenic role of endogenous
N/OFQ, NOP receptor antagonists reversed parkinsonian-like
motor deficits (Marti et al., 2005, 2008; Viaro et al., 2008; Volta et
al., 2010), also synergizing with L-3,4-dihydroxyphenylalanine
(L-DOPA) (Marti et al., 2007; Visanji et al., 2008; Viaro et al.,
2010). Contrary to substantia nigra reticulata (SNr), a reduction
in N/OFQ expression was found in the dopamine (DA)-depleted
striatum (Marti et al., 2010), suggesting a different adaptive re-
sponse of striatal N/OFQ transmission in PD. The striatal
N/OFQ-NOP receptor system has so far received little attention,
possibly due to the low expression of N/OFQ and NOP receptor
in the rodent striatum (Neal et al., 1999a,b).Nonetheless, N/OFQ
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impairs the firing activity of ascendingDA (Marti et al., 2004) and
serotonin (Tao et al., 2007; Nazzaro et al., 2009) neurons, and
inhibits DA (Flau et al., 2002; Olianas et al., 2008) and serotonin
(Sbrenna et al., 2000) release presynaptically. N/OFQ also post-
synaptically counteracts the D1 receptor-stimulated cAMP accu-
mulation in striatal neurons (Olianas et al., 2008), overall
suggesting that endogenous N/OFQ might control striatal func-
tion. This controlmight bemore relevant in the primate caudate/
putamen due to the much greater expression of NOP receptors
(Berthele et al., 2003; Bridge et al., 2003). We therefore investi-
gated whether NOP receptor agonists and antagonists affect the
expression of L-DOPA-induced dyskinesias (LID) in rats (Cenci
et al., 1998) and nonhuman primates (Be´zard et al., 2003). In-
deed, LID are a major motor complication of L-DOPA pharma-
cotherapy thought to originate from aberrant striatal plasticity
(Calabresi et al., 2010). LID are involuntary choreodystonic
movements (Nutt and Gancher, 1994) that develop as a conse-
quence ofDAdenervation and nonphysiological DA release from
both residual DA and serotonin striatal terminals (Carta et al.,
2007; Navailles et al., 2010). This leads to “pulsatile” DA receptor
stimulation and upregulation of D1 signaling (Andersson et al.,
1999; Aubert et al., 2005), increased activity along the Ras/MEK/
ERK kinase pathway (Valjent et al., 2005; Feyder et al., 2011) and
loss of neuronal depotentiation after long-term potentiation
(LTP) induction in striatonigral spiny neurons (Picconi et al.,
2003).
Materials andMethods
In vitro experiments
Immunohistochemistry
Anesthetized 2-month-old C57BL/6 mice were decapitated and the
brains rapidly removed. Slices (200mthick)were cut using a vibratome
keeping the brain submerged in ice-cold carboxygenated sucrose-based
dissecting solution containing the following (inmM): 87 NaCl, 2.5 KCl, 7
MgCl2, 1 NaH2PO4, 75 sucrose, 25 NaHCO3, 10 D-glucose, 0.5 CaCl2,
and 2 kynurenic acid. The slices were transferred into BSC1 chambers
(Scientific System Design) and constantly perfused with carboxygenated
artificial CSF solution containing the following (inmM): 124NaCl, 5KCl,
1.3 MgSO4, 1.2 NaH2PO4, 25 NaHCO3, 10 D-glucose, and 2.4 CaCl2 at a
constant rate of 2 ml/min at 32°C for 1 h. Slices were then stimulated for
10 min with 100 M SKF38393, 1 MN/OFQ, or their combination, and
fixed in 4%paraformaldehyde in 0.1 M sodiumphosphate buffer, pH 7.4,
at room temperature for 15 min. Slices were then rinsed three times for
20 min in 0.1 M sodium phosphate buffer, pH 7.4, at room temperature
and cryoprotected in 30% sucrose overnight at 4°C.
Eighteenmicrometer cryosectionswere cut andwashed three times for
10 min with Dulbecco’s PBS (D-PBS). After blocking in D-PBS contain-
ing 5% normal goat serum and 0.1% Triton X-100 for 1 h at room
temperature, sections were incubated overnight at 4°C with the primary
antibodies: anti-phospho-S6 ribosomal protein (Thr235/236) (1:200;
Cell signaling Technology) and anti-NeuN (1:1000; Chemicon). Sections
were then washed three times for 10 min with D-PBS and incubated for
1 h at room temperature with the secondary antibodies: Alexa Fluor 546
goat anti-mouse (1:200) and Alexa Fluor 488 goat anti-rabbit (1:500)
(Invitrogen).
Following the incubation with the secondary antibodies, the sections
were washed three times for 10 min with D-PBS and the coverslips were
mounted using the fluorescent mounting medium (Dako).
Single- and double-labeled images were obtained using a laser scanning
confocal microscopy (Leica SP2), equipped with the corresponding lasers
and the appropriate filter sets to avoid cross talk between the fluorophores.
Neuronal quantification was performed with ImageJ software on images
taken at 40magnification by counting phospho-S6-immunoreactive neu-
rons among NeuN positive neurons in each slice.
Electrophysiology
Corticostriatal coronal slices (270 m thick) were cut from 1- to
2-month-old male Wistar rats (n  12; Harlan) using a vibratome, as
previously described (Calabresi et al., 1998; Picconi et al., 2003). A single
Figure 1. N/OFQ inhibited D1 receptor-mediated activation of ERK signaling in mouse striatal slices. A, Representative photomicrographs showing ERK-dependent ribosomal protein S6
phosphorylation (pS6 Thr235/236) (green) andNeuN (red) immunofluorescence inmouse striatal slices in response to SKF38393 (100M), N/OFQ (1M), or their combination.B, Phospho-S6 levels
were significantly increased in striatal neurons stimulatedwith SKF38393 (Student’s t test, Control vs SKF38393, t(10)6.452, *p 0.0006). N/OFQ, ineffective by itself, prevented the effect of
SKF38393 (Student’s t test, Control vs SKF38393N/OFQ, t(12) 0.947, p 0.363). One-way ANOVA revealed a significant effect of treatment F(5,31) 27.235, p 0.0001. Bonferroni’s post hoc,
SKF38393 vs SKF38393N/OFQ, #p 0.0001. Data are expressed as number SEM of pS6 positive cells with respect to NeuN positive cells. *p 0.05 different from control. #p 0.05 different
from SKF38393 alone.
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slice was then transferred to a recording chamber and submerged in a
continuously flowing (2.5–3 ml/min) carboxygenated (95% O2-5%
CO2) Krebs solution (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 1.2
NaH2PO4, 2.4 CaCl2, 10 glucose, and 25 NaHCO3 kept at 34°C. Drugs
were bath applied by switching the solution to one containing known
concentrations of drugs. Total replacement of the medium in the cham-
ber occurred within 1 min. Intracellular recordings of striatal medium
spiny neurons (MSNs) were obtained with sharp microelectrodes pulled
fromborosilicate glass pipettes backfilled with 2MKCl (30–60M). An
Axoclamp 2B amplifier (Molecular Devices) was connected in parallel to
an oscilloscope to monitor the signal in “bridge” mode and to a PC for
acquisition of the traces using a pClamp9 software (Molecular Devices).
Only neurons electrophysiologically identified asMSNs were considered
for experiment (Calabresi et al., 1992).
A glutamatergic EPSP was evoked every 10 s by means of a bipolar
electrode connected to a stimulator unit (Grass Telefactor). The stimu-
lating electrode was located in the cortical areas close to the recording
electrode or in the white matter between the cortex and the striatum to
activate corticostriatal fibers. The recording electrodes were invariably
placed within the striatum. The experiments were conducted in aMg2-
free Krebs’ solution to unmask the NMDA glutamate (Glu) receptor
component of the EPSP. After 10–15 min the acquisition of EPSPs of
stable amplitude, a high-frequency stimulation protocol (HFS), consist-
ing of three trains of stimuli at 100 Hz (20 s intertrain interval), was
delivered to the slice to induce LTP of the EPSP (Calabresi et al., 1992).
Twentyminutes after theHFS protocol a low-frequency stimulation pro-
tocol (LFS), consisting of repeated stimuli applied at 2Hz for 10min, was
applied to induce depotentiation of the EPSP amplitude to pre-HFS
conditions (Picconi et al., 2003). Quantitative data are expressed as a
percentage of the EPSP amplitudes in respect to the relative control am-
plitude values, the latter representing the mean of responses recorded
during a stable period. EPSP amplitudesweremeasured 20min afterHFS
or LFS and compared with pre-HFS baseline. Off-line analysis was per-
formed using Clampfit (Molecular Devices) and GraphPad Prism 5
software.
Autoradiography
Twenty micrometer coronal sections were obtained from the frozen
brains of sham-operated, untreated 6-hydroxydopamine (OHDA) le-
sioned and dyskinetic 6-OHDA lesioned (killed 48 h after last L-DOPA
injection)male SpragueDawley rats (see below). Sections were cut at two
different brain levels from bregma: anteroposterior (AP)0.30 to0.92
and 3.60 to 5.80 (Paxinos and Watson, 1986) using a cryostat
(1315°C). Sets of five slides (three slides for total binding and two slides
for nonspecific binding) were used for each group. Iodination of
[Arg14Lys 15Tyr18(di)iodo]N/OFQ-NH2 was performed according to
the Chloramine Tmethod (Hunter and Greenwood, 1962). Briefly, 5 g
of peptide was incubated in 0.05 M phosphate buffer, pH 7.4, for 30 s in
the presence of 0.5 mCi (18.5 MBq) of Na125I and 220 nmol of Chlora-
mine T in a total volume of 85l. The mono-iodinated peptide was then
immediately purified by HPLC on a C18 Jupiter 300 column (250 4,6
mm; Phenomenex) with 0.1% trifluoroacetic acid and acetonitrile as
Figure 2. N/OFQ restored synaptic depotentiation of MSNs in the presence of a D1 receptor agonist. A, Time course of the HFS-induced LTP followed by the LFS-induced depotentiation of MSN
EPSPs in control conditions (n 3, open circles) and in the presence of 0.1M N/OFQ (n 3, filled circles). B, EPSP traces recorded in representative MSNs before HFS (left), and 20min post-HFS
(middle) or LFS (right) in control conditionsand in thepresenceof 0.1MN/OFQ.C, TimecourseofHFS followedbyLFS in thepresenceof 3MD1 receptor agonist SKF38393applied for 20min (white
bar). SKF38393 alone prevented depotentiation in MSNs (control, n 3, open circles) whereas N/OFQ reversed this effect (n 5, filled circles). The NOP receptor antagonist UFP-101 (0.1M)
counteracted theeffect ofN/OFQ (n4,diamonds).D, EPSP traces acquiredbeforeHFSandafterHFSor LFS in thepresenceof SKF38393applied10minafterHFS (top),N/OFQSKF38393 (middle),
and N/OFQ SKF38393 in the presence of UFP-101 (bottom). ***p 0.001 different from control.
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mobile phases. The specific activity of the iodinated peptides corre-
sponds to 2000 cpm/fmol or 1212 Ci/mmol.
The bindingmethod used in this studywas adapted from (Bridge et al.,
2003). Tissue sections were thawed at room temperature and preincu-
bated for 30min in a solution containing: 50mMTris-HCl, pH 7.4; 5mM
MgCl2; and 0.2% bovine serum albumin (BSA). They were then incu-
bated at room temperature for 90 min in the same buffer solution, to
which 5 mg/ml Bacitracin and 150 pM 125I[Tyr14]N/OFQ were added.
Nonspecific binding was determined by adding 1 M cold ligand to the
mixture. Slides were then rinsed in the preincubation solution without
BSA (four rinses, 1 min each), then in distilled water at 4°C (15 s, to
remove the excess of salts) and air dried. Kodak Scientific Biomax MS
films were juxtaposed onto the slides for 3 d at room temperature. Films
were developed in D-19 (Kodak developer) and fixed in Kodak fixer.
Image analysis was performed using a computerized image analysis sys-
tem (MCID; InterFocus GmbH). Specific binding was determined by
subtracting nonspecific binding from total binding taken from adjacent
sections. Calibration was performed on a standard curve generated using
polymer [C14]-microscale standards (GE Healthcare), thereby enabling
conversion of relative optical intensity units, directly measured from
autoradiograms, to binding site density expressed in fmol/mg.
In vivo experiments in rats
Male Sprague Dawley rats (150 g; Harlan) were kept under regular light-
ing conditions (12 h light/dark cycle) and given food and water ad libi-
tum. The experimental protocols performed in rodents were in
accordance with the European Communities Council Directive of No-
vember 24, 1986 (86/609/EEC), and were approved by the ItalianMinis-
try of Health (license #194/2008-B) and the Ethical Committee of the
University of Ferrara. Adequate measures were taken to minimize the
number of animals used and animal pain and discomfort.
Experimental design
Experiments in rats. A total of 126 6-OHDA hemilesioned dyskinetic, 10
6-OHDA hemilesioned naive and 14 sham-operated rats were used.
Pharmacological treatments were randomized and usually administered
every 3 d. A maintenance dose of L-DOPA was administered the day
before treatment, and animals were scored. In experiment using NOP
agonists (see Fig. 3), 20 dyskinetic animals implanted with an intracere-
broventricular cannula received either saline or three doses of N/OFQ,
ON and OFF L-DOPA (n  10 each condition). Another group of 20
animals was treated with saline or three different doses of Ro 65–6570
(i.p.), ON and OFF L-DOPA (n  10 each condition). In microdialysis
experiments (see Fig. 5), six dyskinetic animals were implanted with a
cannula (i.c.v.) and two microdialysis probes in SNr and the ventrome-
dial thalamus (VMTh). Microdialysis was performed for 4 d and treat-
ments (saline, L-DOPA, N/OFQ, and L-DOPA N/OFQ) were given in
a randomized fashion. In experiments using NOP antagonists (see Fig.
6), 10 dyskinetic animals implanted with an intracerebroventricular can-
nula received L-DOPA in combination with saline or UFP-101 (i.c.v.),
whereas another group of 10 animals received L-DOPA in combination
with saline or J-113397 (i.p.). In separate experiments, saline, UFP-101
and J-113397 were also given OFF L-DOPA to measure the impact of
NOP receptor antagonists alone on rotarod performance. Control group
Figure3. NOP receptor agonists attenuated LID. Effect of N/OFQ (0.03–1nmol, i.c.v.) andRo 65–6570 (0.01–1mg/kg, i.p.) onALOAIMs inducedby L-DOPA (6mg/kgplus benserazide 15mg/kg,
i.p.). N/OFQ (A) or Ro 65–6570 (D), given 5 and 30 min before L-DOPA, respectively, attenuated the severity of dyskinesias in a dose-related fashion. N/OFQ and Ro 65–6570 improved rotarod
performance ON L-DOPA (B, E) but worsened it OFF L-DOPA (C, F ). Data are expressed as percentage of the L-DOPA effect measured in the same animal in the last training session, and represent the
mean SEM of 10 determinations. Statistical analysis was performed by conventional (A, D) or RM (B, C, E, F ) one-way ANOVA followed by the Newman–Keuls test for multiple comparisons. A,
Significant effect of treatment (F(11,153) 24.78, p 0.0001). B, Significant effect of treatment (F(3,114) 77.29, p 0.0001), time (F(2,114) 35.08, p 0.0001), and time treatment
interaction (F(6,114)5.42,p0.0001).C, Significant effect of treatment (F(3,114)400.64,p0.0001), butnot time (F(2,114)1.21,p0.30) or time treatment interaction (F(6,114)0.64,
p0.70).D, Significant effect of treatment (F(11,147)11.27,p0.0001).E, Significant effect of treatment (F(3,114)68.86,p0.0001) and time (F(2,114)18.24,p0.0001) butnot time
treatment interaction (F(6,114) 1.10, p 0.36). F, Significant effect of treatment (F(3,114) 387.52, p 0.0001), time (F(2,114) 20.66, p 0.0001), and time treatment interaction (F(6,114)
 5.39, p 0.0001). *p 0.05, **p 0.01, significantly different from saline.
Marti et al. • NOP Agonists and Dyskinesias J. Neurosci., November 14, 2012 • 32(46):16106–16119 • 16109
was injected with saline in both areas. In exper-
iments using regional microinjections (see Fig.
7) 20 dyskinetic rats had a cannula implanted
either in the SNr or dorsolateral striatum
(DLS) (n 10 each group) and received saline
or three doses of N/OFQ in combination with
L-DOPA. Another group of 10 animals was im-
planted both in the SNr and DLS, and received
a single dose ofN/OFQ inDLS, SNr, or both. In
combination experiments (see Fig. 8), 20 dys-
kinetic animals implanted with a cannula in
DLS or SNr (n  10 each) received saline,
N/OFQ (0.1 nmol), UFP-101 (10 nmol), or
N/OFQ  UFP-101, in combination with
L-DOPA. In autoradiography experiment (see
Fig. 9) brain slices were obtained from 8 sham-
operated, 10 6-OHDA hemilesioned, and 10
dyskinetic rats.
Experiments in nonhuman primates. Five
macaques rendered stably parkinsonian with
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and dyskinetic with L-DOPA (see be-
low)(see Fig. 10).
Unilateral lesion with 6-OHDA
Unilateral lesion ofDAneuronswas induced in
isoflurane-anesthetized Sprague Dawley male
rats by stereotaxically injecting 8 g of
6-OHDA(dissolved in 4l of saline containing
0.02% ascorbic acid) into the medial forebrain
bundle (Marti et al., 2005), according to the
following coordinates from bregma: AP 4.4
mm, mediolateral (ML)1.2 mm, and dorso-
ventral (DV) 7.8 mm below dura (Paxinos
and Watson, 1986). Sham-operated animals
were injected with 4 l of saline (containing
0.02% ascorbic acid). Two weeks after
6-OHDA injection, denervation was evaluated
with a test dose of amphetamine (5 mg/kg,
i.p.). Rats showing ipsilateral turning 7
turns/min were enrolled in the study (Marti et
al., 2002a, 2007).
L-DOPA treatment and Abnormal Involuntary Movement
Scale rating
Two weeks after amphetamine testing, DA-depleted rats were made dys-
kinetic by a 21 d course of L-DOPA treatment (6mg/kg benserazide 15
mg/kg, i.p., once daily). Quantification of abnormal involuntary move-
ments (Abnormal Involuntary Movement Scale; AIMs), a correlate of
dyskinesia (Cenci et al., 1998), was performed as extensively described in
previous papers (Lundblad et al., 2002; Mun˜oz et al., 2008; Berthet et al.,
2009;Mela et al., 2010). Briefly, rats were observed individually for 1min
every 20 min during the 3 h that followed L-DOPA injection. Dyskinetic
movements were classified based on their topographic distribution into
three subtypes: (1) axial AIMs, i.e., twisted posture or choreiform twist-
ing of the neck and upper body toward the side contralateral to the lesion;
(2) forelimb AIMs, i.e., jerky or dystonic movements of the contralateral
forelimb and/or purposeless grabbing movement of the contralateral
paw; and (3) orolingual AIMs, i.e., orofacial muscle twitching, empty
masticatory movements and contralateral tongue protrusion. Each AIM
subtype was rated on a frequency scale from 0 to 4 (1, occasional; 2,
frequent; 3, continuous but interrupted by sensory distraction; and 4,
continuous, severe, and not interrupted by sensory distraction) on each
monitoring period (Cenci et al., 1998). In addition, the amplitude of
these AIMswas scored based on a scale from 0 to 4 as described by (Cenci
and Lundblad, 2007). Axial, forelimb, and orolingual (ALO) AIMs were
calculated as the sum of the product of amplitude and frequency scores
from all monitoring periods (Cenci and Lundblad, 2007), and presented
either separately or together (global score). AIMs scoring was performed
five times during L-DOPA treatment; dyskinetic rats showing total AIMs
score 100 in the last session were enrolled in the study. The theoretical
maximal total AIMs score for each animal is 432 (48 each of the nine 20
minute sessions).
Tyrosine immunohistochemistry analysis revealed that dyskinetic rats
were fully DA denervated since the ratio of optical density in the ipsilat-
eral versus contralateral side was 99.1  0.2% in sham-operated and
0.1 0.01% in dyskinetic rats (n 6 both).
Rotarod experiments
The rotarod test was used to quantify the degree of motor impairment
both ON and OFF L-DOPA. Dyskinetic rats were tested before (control
session) and 20, 60, and 120 min after acute drug treatment (L-DOPA,
NOP ligands or their combination). These windows were selected based
on the AIMs time course (data not shown), showing a peak after 60–80
min and extinction after 180 min from L-DOPA administration. The
speed of rotating cylinder was stepwise increased (180 s each step) from 5
rpm until animals fell off the rod (Marti et al., 2004). Dyskinesias nega-
tively correlated with rotarod performance (r0.75, Spearman’s non-
parametric correlation test, p  0.001), with a maximal reduction of
	85% at peak (data not shown).
Drug microinjections in dyskinetic rats
Under isoflurane anesthesia, a stainless steel infusion cannula (15 mm
long, 24 gauge) was stereotaxically lowered over the lateral ventricle [in-
tracerebroventricular: AP  0.9 mm; ML  1.4 mm; ventrodorsal
(VD)2.0 mm; DLS: AP0.7 mm; ML3.5 mm; VD3.2
mm; and/or SNr: AP  5.5 mm; ML  2.2 mm; VD  7.3 mm]
ipsilateral to the lesioned side. A stainless steel stylet was inserted into the
Figure 4. In vivo specificity of NOP receptor agonists. A, B, Ro 65–6570 (0.01–1mg/kg, i.p.) inhibited stepping activity in the
drag test in NOP/mice, being ineffective in NOP/mice. Each experiment consisted of three different sessions: a control
session followedby twoother sessions performed15min (A) and90min (B) after saline or drug administration. Data are expressed
as percentages of motor performance in the control session and are means SEM 6–7 determinations per group. C, D, NOP
receptor antagonists prevent the antidyskinetic effect of NOP receptor agonists. UFP-101 (10 nmol, i.c.v.) was administered
simultaneously with N/OFQ (0.1 nmol, i.c.v.; C) or 5 min before Ro 65–6570 (0.1 mg/kg, i.p.; D). J-113397 (3 mg/kg, i.p.) was
administered 15 min before NOP agonists. Data are expressed as percentages of L-DOPA effect, and are means SEM of 10–12
determinations per group. Statistical analysiswas performedby one-wayANOVA followedby theNewman–Keuls test formultiple
comparisons. A, Significant effect of treatment in NOP/mice (F(3,23) 17.61, p 0.0001). B, Significant effect of treatment
in NOP/mice (F(3,23) 19.89, p 0.0001). *p 0.05, **p 0.01, different from saline. °°p 0.01, different from N/OFQ
or Ro 65–6570 alone.
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cannula to avoid its occlusion. Animals were
allowed 6 d to recover, during which they were
handled to familiarize with the operator and
injection procedures. On the day of experi-
ment, the rat was gently restrained by the op-
erator, the stylet was removed and 0.5 l of
saline (control rats) or saline containing NOP
receptor peptide ligands (N/OFQ and UFP-
101) was injectedwithout the use of anesthesia.
Alternatively, systemic (i.p.) administration of
saline, Ro 65–6570 or J-113397, was per-
formed. In combination studies, NOP ligands
were given 5 min (N/OFQ and UFP-101), 15
min (J-113397), or 30 min (Ro 65–6570) be-
fore L-DOPA.
Microdialysis
Twomicrodialysisprobes (1mmdialyzingmem-
brane,AN69;Hospal)were implanted in theDA-
lesioned SNr (AP5.5,ML2.2, VD8.3) and
ipsilateral VMTh (AP2.3,ML1.4, VD7.4)
of isoflurane-anesthetized dyskinetic rats, as pre-
viously described (Marti et al., 2007, 2008). In the
same surgery session, animals were also im-
planted with an intracerebroventricular cannula
(coordinated as above). Twenty-four hours after
surgery, probes were perfused with a modified
Ringer’s solution (1.2 mMCaCl2, 2.7 mMMgCl2,
148mMNaCl, and 0.85mMMgCl2) at a 3l/min
flow rate and, after 6 h rinsing, samples were col-
lected every 15 min. L-DOPA (6 mg/kg plus
benserazide 15mg/kg)was administered system-
ically (i.p.), whereas N/OFQ 0.1 nmol was in-
jected (i.c.v., 5 min before L-DOPA). In control
rats, saline was injected (i.c.v.) and, 5 min later,
administered intraperitoneally. AIMs monitor-
ing was performed every 15 (for 1 min). At the
end of the experiments, animals were killed and
the correct placement of the probes was verified
histologically.
Endogenous Glu and GABA analysis
Glu and GABAweremeasured by HPLC cou-
pled with fluorometric detection following
o-phthaldialdehyde/mercaptoethanol deri-
vatization (Marti et al., 2007). Glu and GABA
were separated in a 5-C18 Chromsep analytical
column (Chrompack) perfused at 0.48 ml/min
with amobile phase containing 0.1 M sodium ac-
etate, 10% methanol and 2.2% tetrahydrofuran,
pH 6.5). Glu and GABA were detected by a FP-
2020Plus spectrophotometer (Jasco)with the ex-
citation and the emissionwavelengths set at 370
and 450 nm, respectively. The limits of detec-
tion for Glu and GABA were	1 and	0.5 nM,
and their retention timeswere	3.5 and	 18.0
min, respectively.
In vivo experiments in mice
To investigate the in vivo selectivity of Ro 65–
6570, motor activity was evaluated in NOP/
and NOP/ naive mice (25–30 g; 12–15
weeks old) (Nishi et al., 1997) by means of the
drag test. This test measures the ability of the
animal to balance its body posture with fore-
limbs in response to an externally imposed dy-
namic stimulus (backward dragging) (Marti et
al., 2005). The animalwas gently lifted from the
tail allowing the forepaws to rest on the table,
Figure5. N/OFQattenuatedtheelevationofnigralaminoacidsandthereductionof thalamicGABAassociatedwithLID.Dyskinetic rats
wereimplantedwithonemicrodialysisprobeinthelesionedSNrandanother in ipsilateralVMTh.Twenty-fourhours later, ratswereacutely
challengedwithsaline,L-DOPA(6mg/kgplus15mg/kgbenserazide, i.p.),N/OFQ(0.1nmol, i.c.v.),ortheircombination(N/OFQgiven5min
before). In control rats, salinewas injected (i.c.v.) and, 5min later, administered (i.p.). ALOAIMs in arbitrary units (A)weremonitored (for
1min every 15min) simultaneously with GABA and Glu levels in SNr (B, C) and VMTh (D, E) up to 180min from L-DOPA administration.
Microdialysis data were expressed as percentage of basal pretreatment levels (calculated as themean of the two samples preceding the
treatment).DataaremeansSEMof six animals.BasaldialysateGABAandGlu levelswere13.41.0and190.69.7nM, respectively,
in SNr, and 16.7 0.9 and 204.8 8.7 nM, respectively, in VMTh. Statistical analysiswas performed on area-under-the-curve values by
two-wayANOVAfollowedbyNewman–Keuls test formultiple comparisons.A,MaineffectofN/OFQ(F(1,1)80.75,p0.0001), L-DOPA
(F(1,1)472.44,p0.0001), and their interaction (F(1,20)78.63,p0.0001).B,Main effect ofN/OFQ (F(1,1)56.64,p0.0001),
L-DOPA (F((1,1) 158.69, p 0.0001), and their interaction (F(1,20) 21.64, p 0.0001). C,Main effect of N/OFQ (F(1,1) 24.30, p
0.0001), L-DOPA(F(1,1)88.86,p0.0001),andtheir interaction(F(1,20)32.30,p0.0001).D,MaineffectofN/OFQ(F(1,1)40.09,
p0.0001), L-DOPA (F(1,1)17.42,p0.0001), and their interaction (F(1,20)12.01, p0.0001).E,Main effect of N/OFQ (F(1,1)
33.25, p 0.0001), L-DOPA (F(1,1) 169.20, p 0.0001), and their interaction (F(1,20) 46.30, p 0.0001). *p 0.05, **p 0.01
significantly different from saline. ##p 0.01, significantly different from L-DOPA.
Marti et al. • NOP Agonists and Dyskinesias J. Neurosci., November 14, 2012 • 32(46):16106–16119 • 16111
and dragged backwards at a constant speed (	20 cm/s) for a fixed dis-
tance (100 cm). The number of steps made with each paw was recorded
by two distinct observers.
In vivo experiments in nonhuman primates
Experiments were conducted according to previously published proce-
dures and methods (Be´zard et al., 2003; Aubert et al., 2005; Fasano et al.,
2010). Five cynomolgus monkeys (Macaca fascicularis; SAH/Xierxin)
were housed in individual primate cages under controlled conditions of
humidity (50 5%), temperature (24 1°C), and light (12 h light/dark
cycles, time lights on 8:00 A.M.) with food and water ad libitum. Exper-
iments were performed in accordance with European Communities
Council Directive of November 24, 1986 (86/609/EEC) for care of labo-
ratory animals in an Association for Assessment and Accreditation of
Laboratory Animal Care -accredited facility following acceptance of
study design by the Institute of Lab Animal Science (Chinese Academy
of Science, Beijing, China) Institutional Animal Care and Use Commit-
tee. Veterinarians skilled in the healthcare and maintenance of nonhu-
man primates supervised animal care.
Animals were treated daily (9:00 A.M.) withMPTP hydrochloride (0.2
mg/kg, i.v.) dissolved in saline (Bezard et al., 2001a). Following stabiliza-
tion of the MPTP-induced syndrome (2 months), animals received a
tailored dose (16–19 mg/kg) of an L-DOPA/carbidopa combination
(100/25 mg) designed to optimally reverse the parkinsonian features of
each animal, twice daily for 3 months. Animals developed severe and
reproducible dyskinesias, presenting choreic-athetoid (characterized by
constant writhing and jerking motions), dystonic, and sometimes ballis-
ticmovements (large-amplitude flinging and flailingmovements). These
animals were not terminated after completion of experiments, but we
demonstrated in several occasions that animals intoxicated with this reg-
imen display a dramatic reduction of DAergic nigrostriatal markers
(95%) comparedwith control animals (Bezard et al., 2001b; Guigoni et
al., 2005; Fernagut et al., 2010).
Behavioral experiments
Macaque’s behavior was first recorded in the OFF state for 0.5 h in an
observation cage (dimensions: 1.1  1.5  1.1 m). Drugs were then
administered, and behavior was recorded for at least a further 4 h in the
observation cage. The parkinsonian condition (and its reversal) was as-
sessed on a validated parkinsonian monkey rating scale by post hoc anal-
ysis of video recordings by observers blinded to treatment. The
parkinsonian disability score is a combination of the range ofmovement,
bradykinesia, posture, and tremor scores according to the following for-
mula: range of movement  bradykinesia  postural abnormality 
tremor (Be´zard et al., 2003; Aubert et al., 2005; Fasano et al., 2010). The
severity of dyskinesia is rated using the Dyskinesia Disability Scale: 0,
dyskinesia absent; 1, mild, fleeting, and rare dyskinetic postures and
movements; 2, moderate, more prominent abnormal movements, but
not interfering significantly with normal behavior; 3, marked, frequent
and, at times, continuous dyskinesia intruding on the normal repertoire
of activity; or, 4, severe, virtually continuous dyskinetic activity replacing
normal behavior and disabling to the animal. Locomotor activity is con-
Figure 6. NOP receptor antagonists worsened LID. Effect of UFP-101 (10 nmol, i.c.v.) and J-113397 (3 mg/kg, i.p.) on ALO AIMs induced by L-DOPA (6 mg/kg plus benserazide 15 mg/kg, i.p.).
UFP-101 (A) and J-113397 (D), given5and15minbefore L-DOPA, respectively,worsened limbAIMswithout affectingaxial andorolingual AIMs.UFP-101also slightlyworsened rotarodperformance
ON L-DOPA (B) while J-113397 left it unaffected (E). Both compounds improved rotarod performance OFF L-DOPA (C, F ). Data are expressed as percentage of the L-DOPA effectmeasured in the same
animal in the last training session, and represent themean SEM 10 determinations. Statistical analysis was performed by conventional (A,D) or RM (B, C, E, F ) one-way ANOVA followed by the
Newman–Keuls test for multiple comparisons. A, Significant effect of treatment (F(5,60) 5.99, p 0.0001). B, Significant effect of treatment (F(1,54) 7.02, p 0.0106) and time (F(2,54)
12.95, p 0.0001) but not time treatment interaction (F(2,54) 2.83, p 0.0678). C, Significant effect of treatment (F(1,60) 115.65, p 0.0001), time (F(2,60) 17.11, p 0.0001), and
time treatment interaction (F(2,60) 3.29, p 0.0441). D, Significant effect of treatment (F(5,84) 3.056, p 0.0001). E. Significant effect of time (F(2,54) 5.41, p 0.0072) but not
treatment (F(1,54) 0.79, p 0.37) or time treatment interaction (F(2,54) 0.37, p 0.69). F, Significant effect of treatment (F(1,54) 175.12, p 0.0001) but not time (F(2,54) 1.09, p
0.3448) or time treatment interaction (F(2,54) 1.95, p 0.15). *p 0.05, **p 0.01, significantly different from saline.
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comitantly monitored with infrared activity monitors, providing a mo-
bility count every 5min (Be´zard et al., 2003; Aubert et al., 2005; Fasano et
al., 2010).
Data presentation and statistical analysis
Behavior (Figs. 3, 4, 6) and autoradiography (Fig. 9) data were analyzed
using conventional or repeated measure (RM) one-way ANOVA as ap-
propriate, followed by theNewman–Keuls test formultiple comparisons.
Conventional two-way ANOVAwith a 2 2 factorial design was used to
analyze drug interactions (Figs. 5, 7, 8). Nonparametric one-way RM
ANOVA followed by the Dunn’s test for multiple comparisons was used
to treat behavioral scores in nonhuman primates (Fig. 10). p values
0.05 were considered to be statistically significant.
Materials
D-Amphetamine sulfate, benserazide hydrochloride, L-DOPA methyl-
ester hydrochloride,MPTPhydrochloride, 6-OHDAhydrobromide, and
SKF38393were purchased from Sigma. N/OFQ,UFP-101, J-113397, and
Ro 65–6570 were synthesized in our laboratory. All drugs were readily
dissolved in saline.
Results
Effects of N/OFQ on D1 receptor-induced ERK
phosphorylation and loss of synaptic depotentiation
Upregulation of striatal D1 signaling in LID is associated with an
increased activity along the Ras/MEK/ERK kinase pathway
(Valjent et al., 2005; Feyder et al., 2011) and a loss of neuron
capability to depotentiate striatal synaptic response after LTP
induction (Picconi et al., 2003). To investigate the effect of NOP
receptor activation on these D1 receptor-dependent biochemical
correlates of LID, we explored whether N/OFQ could prevent
ERK phosphorylation and restore a physiological depotentiation
of synaptic plasticity in striatal slices of naive animals stimulated
with the D1 receptor agonist SKF38393.
To quantify ERK phosphorylation, we used a recently estab-
lished ex vivo system, in which brain slices prepared from adult
mice can be stimulated with appropriate agonists and antago-
nists. For ERK signaling activation we monitored the ribosomal
protein S6 phosphorylation at the Thr235/236 site (Orellana et
al., 2012). D1 receptor activation by 100 M SKF38393 applica-
tion dramatically elevated ERK signaling by 	10-fold (Fig.
1A,B). N/OFQ 1 M was ineffective alone but prevented the D1
agonist effect (Fig. 1A,B).
Cortically evoked EPSPs were measured in electrophysiologi-
cally identified striatal MSNs (Fig. 2). In a first group of control
slices, after acquiring EPSPs of stable amplitudes for 10min, LTP
of synaptic transmission was induced by HFS protocol (EPSP
amplitude post-HFS, 162.7 6.7%). A subsequent application of
LFS protocol in these recordedMSNs produced a depotentiation
of the synaptic response to pre-HFS conditions (EPSP amplitude
post-LFS, 93.9 7.9%; Fig. 2A,B). Bath application of 3 M D1
receptor agonist SKF38393 prevented depotentiation of MSN
synaptic plasticity (EPSP amplitude post-LFS, 160.8 4.3%; Fig.
2C,D). Bath application of 0.1 M N/OFQ did not affect LTP or
Figure 7. N/OFQ attenuated LID when injected in SNr and DLS. Effect of N/OFQ (0.03–1
nmol, i.c.v.) injected in SNr (A), DLS (B), or both (at 0.1 nmol; C) on ALOAIMs induced by L-DOPA
(6 mg/kg plus benserazide 15 mg/kg, i.p.). N/OFQ given 5 min before L-DOPA attenuated the
severity of dyskinesias in a dose-related fashion, being more potent when injected in DLS than
SNr. Coinjection of N/OFQ in SNr and DLS produced an additive antidyskinetic effect (C). Saline
was simultaneously injected in SNr and DLS. Data are expressed as percentage of the L-DOPA
4
effectmeasured in the same animal in the last training session, and represent themean SEM
of 10 determinations. Statistical analysis was performed by one-way (A, B) or two-way (C)
ANOVA followed by the Newman–Keuls test for multiple comparisons. A, Significant effect of
treatment (F(11,71)9.58,p0.0001).B, Significant effect of treatment (F(11,71)38.8,p
0.0001). C, Main effect of N/OFQ (F(3,60) 528.64, p 0.0001), brain area (F(2,60) 33.94,
p 0.0001), and their interaction (F(6,60) 23.76, p 0.0001). **p 0.01, *p 0.05,
significantly different from saline. °°p 0.01, significantly different from SNr injection. ##p
0.01, significantly different from DLS injection.
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depotentiation in MSNs (EPSP amplitude post-HFS, 152.6 
6.5%; EPSP amplitude post-LFS 106.7 6.0%; Fig. 2A,B). How-
ever, when 3 M SKF38393 was bath applied for 20 min in the
presence of 0.1 M N/OFQ, depotentiation of MSN synaptic
transmission was fully restored (EPSP amplitude, post-LFS
97.3 5.9%, SKF38393 vs SKF38393 N/OFQ, p 0.001; Fig.
2C,D). To verify the selectivity of N/OFQ action, we bath applied
3 M SKF38393 and 0.1 M N/OFQ with 1 M NOP receptor
antagonist UFP-101. In these conditions, LFS protocol did not
produce depotentiation, confirming that N/OFQ action was ac-
complished through the NOP receptor.
Effect of NOP receptor agonists on dyskinesias and rotarod
performance in rats
Data obtained in vitro predict that NOP receptor agonists might
selectively target LID pathways and attenuate LID. We therefore
administered exogenous N/OFQ and the NOP receptor synthetic
agonist Ro 65–6570 (Ro¨ver et al., 2000) to dyskinetic rats chal-
lenged with L-DOPA. N/OFQ (i.c.v.) dose-dependently attenu-
ated LID appearance (Fig. 3A) and rescued rotarod performance
(Fig. 3B) in the 0.03–1 nmol range. The rescue effect at 1 nmol
was, however, less pronounced than at lower doses, consistent
with the finding that N/OFQ caused primary hypolocomotive
effect OFF L-DOPA at this dose (Fig. 3C). To prove the antidyski-
netic potential of NOP receptor agonists, the small molecule Ro
65–6570 was used at doses selective for NOP receptor stimula-
tion (0.01–1 mg/kg, i.p.). Indeed, in this dose range Ro 65–6570
reduced stepping activity in NOP/mice but was ineffective in
NOP/ mice (Fig. 4A,B). Ro 65–6570, given 30 min before
L-DOPA, attenuated AIMs appearance at 0.01 mg/kg (Fig. 3D),
and maximally at 1 mg/kg. This antidyskinetic effect was accom-
panied by restoration of rotarod performance (Fig. 3E). Con-
versely, Ro 65–6570 markedly impaired rotarod performance
OFF L-DOPA at 1mg/kg (Fig. 3F). To confirm the pharmacolog-
ical specificity of the antidyskinetic action of NOP agonists, UFP-
101 and J-113397 prevented the antidyskinetic effect of N/OFQ
and Ro 65–6570 (Fig. 4C,D).
Effects of intracerebroventricular injections of N/OFQ on
LID and neurochemical correlates in SNr and VMTh
Microdialysis was used to investigate whether the antidyskinetic
action of N/OFQ was accompanied by changes of the nigral out-
put. AIMs expression (Fig. 5A) was associated with a 	2-fold
elevation of GABA and Glu in SNr (Fig. 5B,C) as well as a	40%
reduction of GABA and a	60% elevation of Glu in VMTh (Fig.
5D,E). Injection of 0.1 nmol N/OFQ (i.c.v.) attenuated (	60%)
LID severity (Fig. 5A) and simultaneously blunted the surge in
nigral amino acids (Fig. 5B,C). In addition, N/OFQ prevented
theGABA inhibition and attenuated theGlu surge in VMTh (Fig.
5D,E).
Effect of NOP receptor antagonists on dyskinesias and
rotarod performance in rats
To investigate whether not only exogenous but also endogenous
N/OFQ affected LID, peptidic (UFP-101) (Calo et al., 2002) and
nonpeptidic (J-113397) (Kawamoto et al., 1999) NOP receptor
antagonists were used at maximal antiparkinsonian doses (Marti
et al., 2005) against a prodyskinetic dose of L-DOPA. UFP-101
(10 nmol, i.c.v.; Fig. 6A) or J-113397 (3 mg/kg, i.p.; Fig. 6D)
worsened limbwithout affecting axial and orolingual AIMs.Con-
sistently, neither antagonist attenuated the impairment of ro-
tarod performance associated with LID (ON L-DOPA; Fig.
6B,E). Conversely, UFP-101 (Fig. 6C) and J-113397 (Fig. 6F)
facilitated rotarod performance OFF L-DOPA.
Effect of regional injections of N/OFQ in the SNr and DLS of
dyskinetic rats
To investigate the brain areas involved in the antidyskinetic and
prodyskinetic effects of NOP receptor ligands, N/OFQ and UFP-
101 were microinjected in SNr and/or DLS. Intranigral N/OFQ
slightly reduced limb AIMs at 0.1 nmol providing a greater and
Figure 8. UFP-101worsened LIDwhen given in SNr but not DLS, preventing N/OFQ action in
both regions. Effect of injections of N/OFQ (0.1 nmol, i.c.v.), UFP-101 (10 nmol, i.c.v.), or their
combinations in SNr (A) or DLS (B) on ALO AIMs induced by L-DOPA (6 mg/kg plus benserazide
15 mg/kg, i.p.). UFP-101 was administered 5 min before L-DOPA, simultaneously with N/OFQ.
Data are expressed as percentage of the L-DOPA effect measured in the same animal in the last
training session, and represent themean SEM of 10 determinations. Statistical analysis was
performed by two-way ANOVA followed by the Newman–Keuls test for multiple comparisons.
A, LimbAIMs,main effect of N/OFQ (F(1,1) 12.95, p 0.0012), UFP-101 (F(1,1) 16.00, p
0.0004), and their interaction (F(1,28) 29.18, p 0.0001); axial AIMs, main effect of N/OFQ
(F(1,1) 13.63, p 0.0012), UFP-101 (F(1,1) 45.11, p 0.0001), and their interaction
(F(1,28) 12.38, p 0.0015); orolingual AIMs, main effect of N/OFQ (F(1,1) 26.90, p
0.0001), UFP-101 (F(1,1) 24.54, p 0.0001), and their interaction (F(1,28) 22.93, p
0.0001). B, Limb AIMs, main effect of N/OFQ (F(1,1) 192.51, p 0.0001), UFP-101 (F(1,1)
12.64, p 0.0014), and their interaction (F(1,28) 9.42, p 0.0047); axial AIMs, main effect
of N/OFQ (F(1,1) 64.43, p 0.0001) but not UFP-101 (F(1,1) 0.01, p 0.89) or their
interaction (F(1,28) 3.65, p 0.07); orolingual AIMs, main effect of UFP-101 (F(1,1) 8.99,
p 0.0056) but not N/OFQ (F(1,1) 0.02, p 0.98) or their interaction (F(1,28) 0.10, p
0.74). **p 0.01, significantly different from saline.
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more generalized effect at 1 nmol (Fig. 7A). Conversely, intrastri-
atal N/OFQ caused a marked reduction of limb and axial AIMs
yet at 0.03 nmol (Fig. 7B). Combined intranigral and intrastriatal
injections of 0.1 nmol N/OFQ (Fig. 7C) caused greater AIMs
attenuation than each injection alone. Contrary to N/OFQ, UFP-
101 (10 nmol) worsened limb and axial AIMs when injected in
SNr (Fig. 8A) but not striatum (Fig. 8B). In both cases, however,
UFP-101 prevented the antidyskinetic effect of locally injected
N/OFQ.
NOP receptor binding associated with parkinsonism
and dyskinesias
To investigate whether LID is associated with changes of NOP
receptor binding, quantitative autoradiographywas used (Fig. 9).
In sham-operated rats, binding appeared highest inmotor cortex
(M1 andM2), intermediate in striatum and SN, and lowest in the
subthalamic nucleus of (Fig. 9A,E) (Table 1). 6-OHDA lesioning
(Fig. 9B,F) caused an increase of ipsilateral binding throughout
the striatum and a reduction in both SN subdivisions (Fig.
9D,H). Similar patterns were observed in the brain of dyskinetic
rats (Fig. 9C,D,G–H).
NOP receptor agonists in dyskinetic nonhuman primates
To confirm the antidyskinetic potential of NOP receptor ago-
nists, Ro 65–6570 was systemically injected in MPTP-lesioned
dyskinetic macaques (Fig. 10A). Ro 65–6570 significantly re-
duced dyskinetic movements at 0.01 mg/kg (i.m.) but not lower
dose (Fig. 9B). Ro 65–6570 was effective against dystonia, al-
though a trend for inhibition of chorea was clearly observed (Fig.
10B). Time-course analysis (Fig. 10C,D) revealed that Ro 65–
6570 attenuated the peak and shortened the duration of dyski-
netic movements. Ro 65–6570 did not affect the therapeutic
effects of L-DOPA on movement range, bradykinesia, and
tremor, and even improved posture at the higher dose (Table 2).
Discussion
Opposite adaptive changes of N/OFQ transmission have been
observed in the basal ganglia of the parkinsonian rodent brain:
elevation of N/OFQ expression (and release) accompanied by
reduction of NOP receptor binding in SNr, and reduction of
N/OFQ expression accompanied by elevation of NOP receptor
binding in striatum. These changes underlie the different behav-
Figure9. LIDwas associatedwith an elevation ofNOP receptor binding in the striatumanda reduction in the SN. Representative total binding of 125I[Tyr 14]N/OFQ toNOP receptors in cortical and
subcortical areas of sham-operated (A, E), hemiparkinsonian (B, F), and dyskinetic (C,G) rats. Twentymicrometer coronal sections were cut at two different brain levels from bregma: AP0.30 to
0.92 and3.60 to5.80. Specific binding values, given in Table 1, were obtained by subtraction of nonspecific from total binding. Binding changes are expressed as percentage of the
contralateral hemisphere (D,H) and aremeans SEM of 6 –10 animals. Statistical analysis was performed by one-way ANOVA followed by Newman–Keuls test for multiple comparisons.
**p 0.01, significantly different from sham-operated rats.
Table 1. Autoradiographical binding of 125I
Tyr 14N/OFQ to the NOP receptor in
cortical and subcortical areas of sham-operated, untreated 6-OHDA lesioned
(hemiparkinsonian), and dyskinetic rats
Sham operated Hemiparkinsonian Dyskinetic
Level AP0.30 to0.92 mm
M1
Ipsi 71.6 6.7 89.8 14.9 94.6 6.1
C/L 77.2 7.6 83.8 14.1 90.6 6.2
M2
Ipsi 80.8 8.6 90.9 14.9 100.3 6.8
C/L 81.1 6.1 90.0 13.7 97.5 6.9
CPuDL
Ipsi 22.7 4.8 30.6 6.2 31.5 3.5
C/L 23.0 4.9 20.9 4.5 21.5 3.0
CPuVL
Ipsi 24.8 4.7 30.1 3.9 34.3 3.1
C/L 25.9 4.7 22.5 3.8 25.9 2.8
CPuDM
Ipsi 24.8 4.9 28.6 3.0 30.4 3.4
C/L 26.1 4.7 19.2 1.5 21.6 3.1
CPuCe
Ipsi 27.0 6.4 27.7 4.2 30.6 3.7
C/L 27.7 6.5 20.7 3.4 23.1 3.6
CPuVM
Ipsi 29.7 3.0 39.5 6.3 36.9 3.1
C/L 29.5 3.1 30.0 5.3 27.1 3.0
Level AP3.60 to5.80 mm
M1
Ipsi 72.4 6.8 89.7 13.9 96.6 7.2
C/L 75.4 8.6 84.8 12.1 94.6 7.3
M2
Ipsi 78.4 5.0 85.7 14.0 90.1 7.5
C/L 76.4 8.6 84.8 13.0 91.0 7.8
STN
Ipsi 17.4 1.7 32.3 6.1 35.4 7.0
C/L 18.5 4.1 30.9 6.0 38.5 7.4
SNr
Ipsi 25.5 1.3 16.0 4.6 16.6 4.4
C/L 25.1 2.7 28.1 4.9 26.8 4.7
SNc
Ipsi 22.9 0.6 17.7 3.9 19.9 3.4
C/L 24.6 1.8 34.7 3.2 32.1 4.8
Twenty micrometer coronal sections were cut at two different brain levels from bregma: AP0.30 to0.92 and
3.60 to5.80. Absolute binding values are given as fmol/mg tissue. Ce, Cerebellar; CPu, caudate-putamen; DL,
dorsolateral; DM, dorsomedial; VL, ventrolateral; VM, ventromedial.
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ioral responses toNOP receptor ligands in
PD models. Indeed, we have previously
reported that NOP receptor antagonists
exert a symptomatic antiparkinsonian ef-
fect (Marti et al., 2005, 2008; Viaro et al.,
2008, 2010; Visanji et al., 2008; Volta et al.,
2010), and that such effect is mediated by
blockade of SNr NOP receptors (Marti et
al., 2005, 2010). We now report that NOP
receptor agonists provide an antidyski-
netic effect, which is faithfully replicated
by intrastriatal N/OFQ injections, sug-
gesting the involvement of striatal NOP
receptors. LIDs are associated with hyper-
esponsiveness of upregulated D1 recep-
tors on striatonigral MSNs (Aubert et al.,
2005; Berthet et al., 2009) leading to an
increased activity along the Ras/MEK/
ERK kinase pathway (Valjent et al., 2005;
Feyder et al., 2011) and a loss of neuron
capability to depotentiate striatal synaptic
response after LTP induction (Picconi et
al., 2003). In vitro and in vivo data revealed
that NOP receptor activation opposes D1
signaling in striatum. Indeed, N/OFQ
prevented the D1 receptor-mediated in-
crease in ERKphosphorylation and loss of
striatal depotentiation of striatal plasticity
in striatal MSNs, without being per se ef-
fective. These data add to the previous
finding that N/OFQ inhibited the D1 re-
ceptor stimulated cAMP accumulation in
striatal slices (Olianas et al., 2008) and suggest the existence of a
negative interaction between the NOP and D1 receptor on the
membranes of striatal MSNs. The NOP receptor is expressed not
only presynaptically on nigrostriatal DA terminals (Norton et al.,
2002) but also postsynaptically on striatal GABAergicMSNs neu-
rons (Olianas et al., 2008). The postsynaptic action of N/OFQ
might be favored under dyskinetic conditions, since in the stria-
tum of L-DOPA primed and unprimed 6-OHDA hemilesioned
rats, NOP receptor binding is upregulated, probably to compen-
sate for the reduction of N/OFQ expression following DA dener-
vation (Marti et al., 2010). Thus, NOP receptor agonists would
reinstate an inhibitory control mediated by endogenous N/OFQ
over striatal D1 signaling, which has been lost following DA de-
nervation.
Indirect evidence that the negative NOP receptor modulation
of D1 signaling is relevant for in vivo conditions was provided by
microdialysis experiments showing that centrally administered
N/OFQ attenuated LID simultaneously with the surge of GABA
levels in SNr. In fact, the same responses were observed in dyski-
netic rats by pairing systemic L-DOPAwith intrastriatal perfusion
of a D1 receptor antagonist (Mela et al., 2012). This endorses the
view that the antidyskinetic effect of N/OFQ is possibly mediated
by upregulated postsynaptic NOP receptors opposing the over-
activation of the direct striatonigral pathway induced by L-DOPA
via D1 receptors. Consistently, microdialysis also revealed that
LIDwas associatedwith inhibition of thalamicGABA release, and
that the antidyskinetic action of N/OFQ was accompanied by
blockade of this response. Indeed, inhibition of thalamic GABA
might reflect overinhibition of nigrothalamic neurons by direct
striatonigral pathway activation, as previously demonstrated for
the anti-akinetic effect of L-DOPA in hemiparkinsonian rats
(Marti et al., 2007). This lends neurochemical support to the
notion that overinhibition of nigrothalamic GABA neurons by
striatonigral direct pathway activation underlies both the motor
promoting and prodyskinetic actions of L-DOPA.
Remarkably, the antidyskinetic action of N/OFQ was not ac-
companied bymotor inhibition. Indeed, it is well known that one
of the main consequences of central NOP receptor stimulation is
motor impairment (Reinscheid et al., 1995; Devine et al., 1996;
Jenck et al., 1997; Marti et al., 2004, 2009). However, the anti-
dyskinetic effect of N/OFQ and Ro 65–6570 was observed at
doses approximately 30- to 100-fold lower than those causing
hypolocomotion, suggesting it was not related to motor impair-
Figure 10. Ro 65–6570 attenuated LID in MPTP-treatedmacaques. Five stably parkinsonianmacaques weremade dyskinetic
by chronic L-DOPA treatment, and then challengedwith L-DOPA combinedwith Ro65–6570 (0.001 and0.01mg/kg, i.m.) or saline
(A). Dyskinetic conditions were assessed on a Dyskinesia Disability Scale (see Materials and Methods) evaluating choreiform and
dystonic components (A, B). The time courses of these motor responses are shown in C and D. Data are expressed as absolute
dyskinesia scores in each animal (A), medians with lower and upper quartiles (B), or means SEM (C,D). Statistical analysis was
performed by one-way nonparametric RM ANOVA (Friedman test) followed by the Dunn’s test for multiple comparisons. *p
0.05, significantly different from saline.
Table 2. Motor behavior of MPTP-treatedmacaques before (OFF score) and after
(ON score) L-DOPA and Ro 65–6570 administration
OFF score
ON score
Saline
Ro 65–6570
0.001 mg/kg
Ro 65–6570
0.01 mg/kg
Chorea 0.0 0.0 23.8 3.3 16.8 3.5 15.4 4.1
Dystonia 0.0 0.0 23.8 3.3 15.8 3.6 16.0 4.4*
Total dyskinesia 0.0 0.0 47.6 6.6 32.8 7.1 31.4 8.4*
Movement 2.4 2.4 39.4 1.9 39.4 1.5 40.0 1.7
Bradykinesia 36.0 0.0 9.4 1.7 8.6 2.2 8.6 3.0
Posture 19.2 2.9 7.2 1.5 3.6 1.6 1.8 1.1*
Tremor 2.4 2.4 0.6 0.6 1.0 0.5 3.2 1.4
Total parkinsonian disability 103.2 6.1 25.8 4.7 21.8 4.9 21.4 6.2
Five stably parkinsonian macaques were made dyskinetic by chronic L-DOPA treatment. Macaques were then chal-
lengedwith L-DOPA combinedwith Ro 65–6570 (0.001 and 0.01mg/kg, i.m.) or saline. Parkinsonian conditionwas
assessedonaparkinsoniannonhumanprimate rating scale scoringmovement range, bradykinesia, posture, tremor,
and total parkinsonian disability (see Materials and Methods). Dyskinetic condition was assessed on a Dyskinesia
Disability Scale evaluating choreiform, dystonic, and total dyskinesiamovements (seeMaterials andMethods). Data
are meansmeans from five animals. Statistical analysis was performed by nonparametric one-way RM ANOVA
followed by Dunn’s test for multiple comparisons. *p 0.05, versus saline.
16116 • J. Neurosci., November 14, 2012 • 32(46):16106–16119 Marti et al. • NOP Agonists and Dyskinesias
ment. Thus, NOP receptor agonists might behave as functional
DA antagonists that can be dosed in a way to improve LID with-
out affecting movement in the OFF state.
N/OFQ also attenuated dyskinesia when injected into SNr.
Indeed, SNr is involved in LID (Meissner et al., 2006; Westin et
al., 2006; Lindgren et al., 2010). In particular, conversion of
L-DOPA to DA in SNr (Sarre et al., 1998) generates abnormal
nigral DA levels (Lindgren et al., 2010) thereby triggering dyski-
netic movements through activation of both D1 and D2 nigral
receptors (Mela et al., 2012). However, different from striatum,
the hypolocomotive and antidyskinetic doses of N/OFQ given
intranigrally largely overlapped, suggesting that attenuation of
LID is due to unspecific motor inhibition. Indeed, exogenous
N/OFQmicroinjected in the SNr of naive rats inhibitsmovement
(Marti et al., 2004, 2009), possibly through elevation of the excit-
atory Glu (Marti et al., 2002b) and attenuation of the inhibitory
GABA inputs (Marti et al., 2007;Mabrouk et al., 2010) impinging
over nigrothalamic neurons. Alternatively, we could speculate
that dyskinesia pathways in SNr are less sensitive to N/OFQ, or
even that N/OFQ itself is less active in the DA-depleted SNr.
Indeed, the enhancement of the N/OFQ tone in SNr along with
the reduction of the NOP receptor binding (present study) and
expression following DA depletion (Marti et al., 2005, 2010) pre-
dict a higher NOP receptor saturation by endogenous N/OFQ,
which favors the motor promoting and antiparkinsonian action
of NOP receptor antagonists (Marti et al., 2007, 2008; Volta et al.,
2011).
Previous studies have demonstrated the potential therapeutic
benefit of a combination of subthreshold doses of an NOP recep-
tor antagonist with L-DOPA in parkinsonian rodents (Marti et
al., 2007; Viaro et al., 2010).We now report that anNOP receptor
antagonist given in SNr worsens dyskinesia severity when com-
bined with dyskinesiogenic doses of L-DOPA. This corroborates
the view that NOP receptor blockade in SNr potentiates the an-
tiparkinsonian action of L-DOPA at the cost of inducing dyski-
nesia, as also observed in marmosets (Visanji et al., 2008).
Although the prodyskinetic effect induced by intracerebroven-
tricularUFP-101 and systemic J-113397wasmild, limited to limb
dyskinesia and observed at maximal antagonist doses, this find-
ing warns of the potential motor side effects of overdosing NOP
antagonists as an adjunct to L-DOPA therapy.
The antidyskinetic effect of Ro 65–6570 was also replicated in
the gold-standard model of LID, the dyskinetic macaque. The
effect of Ro 65–6570 was milder than in rats, but occurred in the
same dose range. Axial symptoms such as gait and balance dis-
turbances are very common and disabling in PD patients (Jank-
ovic, 2008). The finding that an NOP agonist improved posture
in L-DOPA-treated dyskineticmacaquesmight contrast with pre-
vious findings that an NOP antagonist improved balance in
MPTP-treated L-DOPA-unprimedmacaques (Viaro et al., 2008).
The apparent contradiction that an NOP agonist and an antago-
nist have the same impact on axial symptomsmight be explained
on the basis of an action at NOP receptors (possibly located in
different brain areas/circuits) that are differently saturated by
endogenous N/OFQ.Moreover, we should recall that the models
and timing of administration were different in the two studies.
Indeed, the overall behavioral patterns were different since the
NOP antagonist also improved bradykinesia, tremor, hypokine-
sia, and rigidity, whereas the NOP agonist did not.
Concluding remarks
A major side effect of long-term therapy with L-DOPA is the
development of dyskinesias (Nutt and Gancher, 1994; Bezard et
al., 2001a; Obeso et al., 2004; Calabresi et al., 2010), which repre-
sent a clinical challenge due to the poor therapeutic armamentar-
ium available to neurologists, essentially limited to amantadine
(Verhagen Metman et al., 1998). Here we report that exogenous
N/OFQ and the small molecule NOP receptor agonist Ro 65–
6570 inhibited LID expression in dyskinetic rats and macaques
without attenuating the antiparkinsonian effect of L-DOPA. We
also provide evidence that N/OFQ inhibited biochemical, elec-
trophysiological, and neurochemical correlates of striatal D1 re-
ceptor activation in the naive or dyskinetic striatum, which
suggests that NOP receptor agonists exert a selective antidyski-
netic effect by activating striatal NOP receptors that oppose D1
signaling. However, further mechanistic studies in 6-OHDA le-
sioned dyskinetic and nondyskinetic rats need to be performed to
confirm this hypothesis. The possibility that NOP receptor ago-
nists exert an antidyskinetic effect through striatal NOP receptor
does not contradict our previous finding that NOP receptor an-
tagonists exert antiparkinsonian effects through blockade of
NOP receptors in SNr. Indeed, an NOP receptor antagonist is
expected to act primarily where the N/OFQ tone is elevated (i.e.,
in SNr), whereas anNOP receptor agonistwhereN/OFQ is lowor
absent (i.e., in striatum).
In conclusion, NOP receptor agonists have been proven effec-
tive for treating pain (Ko et al., 2009), anxiety (Jenck et al., 1997),
and drug dependence (Zaveri, 2011). The concordance of the
antidyskinetic effects in rats and nonhuman primates suggests
that NOP receptor agonists may also prove effective in attenuat-
ing LID and rescuing motor activity in dyskinetic PD patients.
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